Skip to content
Search

Latest Stories

UK virus variant has developed concerning new mutation in small number of cases

Pb Staff writer
By Pb Staff writerFeb 02, 2021
Pb Staff writer
See Full Bio

The UK variant of the coronavirus has developed a new, concerning mutation in a small number of cases, which scientists said makes it similar to the South African and Brazilian variants and could reduce the efficacy of vaccines.

The emergence of the mutation to the variant first discovered in Britain highlights how complicated exiting COVID-19 lockdown will be even once vaccines are rolled out.

Public Health England said there had been 11 reports of the UK variant which feature the E484K mutation, mostly in south-west England.

The E484K mutation, which occurs on the spike protein of the virus, is the same change as has been seen in the South African and Brazilian variants that have caused international concern.

“PHE is monitoring the situation closely and all necessary public health interventions are being undertaken, including enhanced contact tracing and control measures,” a PHE spokesman said.

Several laboratory studies have found that vaccines and antibody therapy are less effective against the South African variant.
By contrast, early evidence showed that vaccines worked just as well against the UK variant, which originally did not have the E484K mutation.
Health secretary Matt Hancock said it was too early to tell the impact of variants on vaccines, but mutations of concern had been reported in Bristol and Liverpool.
“We must continue to act with caution, not least because of the renewed challenges posed by new variants of the coronavirus,” he told lawmakers.
Calum Semple, who is part of a panel that advises the government, told BBC radio that E484K was the “mutation of most concern”, and had “occurred spontaneously” in the UK variant.
The name E484K, in layman’s terms, is like map coordinates. The number 484 is the exact location of the mutation, the letter E is the amino acid that it was originally and the letter K is the amino acid that it has mutated to.
Concern over the South African variant, with its E484K mutation, has already prompted authorities in England to begin a door-to-door mass testing drive in areas where cases of the variant have been found in people with no link to South Africa, while mandatory quarantine in hotels for arrivals from South Africa is yet to come into force.
Though the number of reported cases of the UK variant with the concerning mutation are small, scientists said that it demonstrated how Britain’s high prevalence of cases meant that it was not enough simply to prevent new variants being imported.
“This report would seem to suggest that under conditions of very high levels of virus replication even the most stringent of border controls, although they may delay spread, are unlikely to prevent the appearance of new variants,” said Jonathan Stoye, virologist at The Francis Crick Institute.

Related News

Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling
News

Pharma imports to US surged in March as drugmakers look to avoid tariffs

WW International logo with bold bankruptcy notice and confident recovery statement

US diet company WeightWatchers files for bankruptcy

Scottish community pharmacist working in high street pharmacy with supportive environment
News

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK
News

Aspire acquires UK distribution rights from Tetris

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Pharmacist declining participation in assisted dying under new UK legislation

It could take another four years for assisted dying to become law

Pic credit: iStock

Pharmacists to have choice to opt-out of assisted dying process

Pharmacists will not be forced to be a part in assisted dying cases with the MP leading the campaign expected to made amendments to the bill which is currently going through parliamentary process.

Kim Leadbeater, the MP behind the Terminally Ill Adults (End of Life) Bill, will say that “no person is under any duty to participate in the provision of assistance”.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc